BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $23
Hold Rating on Arcus Biosciences Amid TIGIT Inhibitor Uncertainties
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $25
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Arcus Biosciences (RCUS)
Leerink Partners Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $46
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Taysha Gene Therapies (TSHA) and Y-Mabs Therapeutics (YMAB)
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Arcus Biosciences Analyst Ratings
Barclays Gives a Buy Rating to Arcus Biosciences (RCUS)
Analysts' Top Healthcare Picks: Arcus Biosciences (RCUS), Argenx Se (ARGX)
Arcus Biosciences (RCUS) Receives a Buy From BTIG
Barclays Maintains Overweight on Arcus Biosciences, Lowers Price Target to $25
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences Analyst Ratings
Arcus Biosciences Analyst Ratings
Truist Lowers Price Target on Arcus Biosciences to $44 From $50, Maintains Buy Rating
Arcus Biosciences Analyst Ratings